Erythrocytes as Carriers of Therapeutic Enzymes

Pharmaceutics

BridgetE. Bax¹ 

[1] Molecular and Clinical Sciences, St. George’s, University of London, London SW17 0RE, UK;

关键词: carrier erythrocytes;    erythrocyte carriers;    enzyme replacement therapies;    therapeutic enzymes;    thrombolytic therapy;    drug delivery;   

DOI  :  10.3390/pharmaceutics12050435

来源: DOAJ

【 摘 要 】

Therapeutic enzymes are administered for the treatment of a wide variety of diseases. They exert their effects through binding with a high affinity and specificity to disease-causing substrates to catalyze their conversion to a non-noxious product, to induce an advantageous physiological change. However, the metabolic and clinical efficacies of parenterally or intramuscularly administered therapeutic enzymes are very often limited by short circulatory half-lives and hypersensitive and immunogenic reactions. Over the past five decades, the erythrocyte carrier has been extensively studied as a strategy for overcoming these limitations and increasing therapeutic efficacy. This review examines the rationale for the different therapeutic strategies that have been applied to erythrocyte-mediated enzyme therapy. These strategies include their application as circulating bioreactors, targeting the monocyte–macrophage system, the coupling of enzymes to the surface of the erythrocyte and the engineering of CD34⁺ hematopoietic precursor cells for the expression of therapeutic enzymes. An overview of the diverse biomedical applications for which they have been investigated is also provided, including the detoxification of exogenous chemicals, thrombolytic therapy, enzyme replacement therapy for metabolic diseases and antitumor therapy.

【 授权许可】

Unknown